Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer
Rafael Rosell, Teresa Morán, Cristina Queralt et al. · New England Journal of Medicine · 2009
BACKGROUND: Activating mutations in the epidermal growth factor receptor gene (EGFR) confer hypersensitivity to the tyrosine kinase inhibitors gefitinib and erlotinib in patients with advanced non-small-cell lung cancer. We evaluated the feasibility of large-scale screening for EGFR mutations in such patients and analyzed the association between the mutations and the outcome of erlotinib treatment. METHODS: From April 2005 through November 2008, lung cancers from 2105 patients in 129 institutions in Spain were screened for EGFR mutations. The analysis was performed in a central laboratory. Patients with tumors carrying EGFR mutations were eligible for erlotinib treatment. RESULTS: EGFR mutations were found in 350 of 2105 patients (16.6%). Mutations were more frequent in women (69.7%), in patients who had never smoked (66.6%), and in those with adenocarcinomas (80.9%) (P<0.001 for all comparisons). The mutations were deletions in exon 19 (62.2%) and L858R (37.8%). Median progression-free survival and overall survival for 217 patients who received erlotinib were 14 months and 27 months, respectively. The adjusted hazard ratios for the duration of progression-free survival were 2.94 for men (P<0.001); 1.92 for the presence of the L858R mutation, as compared with a deletion in exon 19 (P=0.02); and 1.68 for the presence of the L858R mutation in paired serum DNA, as compared with the absence of the mutation (P=0.02). The most common adverse events were mild rashes and diarrhea; grade 3 cutaneous toxic effects were recorded in 16 patients (7.4%) and grade 3 diarrhea in 8 patients (3.7%). CONCLUSIONS: Large-scale screening of patients with lung cancer for EGFR mutations is feasible and can have a role in decisions about treatment.
Cited by 2,367 works. doi:10.1056/nejmoa0904554 Open-access PDF
Authors
- Rafael Rosell
- Teresa Morán
- Cristina Queralt
- Rut Porta
- Carlos Camps
- Margarita Majem
- Guillermo López-Vivanco
- Dolores Isla
- Mariano Provencio
- Amelia Insa
- Bartomeu Massutí
- J.L. González-Larriba
- Luis G Paz-Ares
- Isabel Bover
- Rosario García‐Campelo
- Miguel Ángel Moreno
- Sílvia Catot
- Christian Diego Rolfo
- Noemı́ Reguart
References
- Activating Mutations in the Epidermal Growth Factor Receptor Underlying Responsiveness of Non–Small-Cell Lung Cancer to Gefitinib
- EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
- EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib
- Comparison of Four Chemotherapy Regimens for Advanced Non–Small-Cell Lung Cancer
- COMPARISON OF FOUR CHEMOTHERAPY REGIMENS FOR ADVANCED NON-SMALL-CELL LUNG CANCER
- Somatic mutations affect key pathways in lung adenocarcinoma
- Clinical and Biological Features Associated With Epidermal Growth Factor Receptor Gene Mutations in Lung Cancers
- Global Survey of Phosphotyrosine Signaling Identifies Oncogenic Kinases in Lung Cancer
- Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
- Mutations of the Epidermal Growth Factor Receptor Gene Predict Prolonged Survival After Gefitinib Treatment in Patients With Non–Small-Cell Lung Cancer With Postoperative Recurrence